Figure 1.

Likelihood of distant relapse in patients with residual cancer burden (RCB) -0 (pCR), RCB-I (npCR, minimal residual disease), RCB-II (moderate residual disease), or RCB-III (extensive residual disease). P value is from a log-rank test for difference between all survival curves. RCB is calculated as a continuous index combining pathologic measurements of primary tumor (size and cellularity) and nodal metastases (number and size) to predict distant relapse-free survival (calculator available online at: http://www.mdanderson.org/breastcancer_RCB). Reproduced with permission from Symmans et al. 2007 ¹³.